Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 25, 2022
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
Tue, May 24, 2022
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
Salveen Richter Maintained (ATRA) at Strong Sell with Decreased Target to $100 on, May 24th, 2022
Salveen Richter of Goldman Sachs, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Sell with Decreased Target from $125 to $100 on, May 24th, 2022.
Salveen has made no other calls on ATRA in the last 4 months.
There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 1 agrees with Salveen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yigal Nochomovitz of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $200 on, Tuesday, May 10th, 2022
These are the ratings of the 2 analyists that currently disagree with Salveen
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $725 on, Monday, May 23rd, 2022
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $550 on, Monday, March 28th, 2022
